OptimiTM-03.jpg
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
May 22, 2024 08:30 ET | Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
blue-mountain-logo-blue 1 1.png
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
May 21, 2024 09:00 ET | Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
OptimiTM-03.jpg
Optimi Health Provides Corporate Update
May 10, 2024 08:50 ET | Optimi Health Corp.
Optimi Health provides corporate update.
blue-mountain-logo-blue 1 1.png
Blue Mountain Appoints Global Head of Marketing to Bolster Growth and Secure its Position as the EAM Industry Standard in the Life Sciences Sector
April 24, 2024 09:00 ET | Blue Mountain
STATE COLLEGE, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, is pleased to announce the appointment...
OptimiTM-03.jpg
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
April 23, 2024 08:18 ET | Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
blue-mountain-logo-blue 1 1.png
Blue Mountain Achieves SOC 2 Compliance, Demonstrating Commitment to Data Security and Trustworthiness
April 10, 2024 09:00 ET | Blue Mountain
STATE COLLEGE, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant EAM (Enterprise Asset Management) software for life sciences, proudly announces its achievement of...
OptimiTM-03.jpg
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
April 09, 2024 09:13 ET | Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
PharmAla Biotech Logo 800 x 422.png
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET | PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
OptimiTM-03.jpg
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
April 02, 2024 07:30 ET | Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Signs Sale Agreement with Numinus
March 26, 2024 08:55 ET | PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference